Drug intelligence / Profile preview

Amplivax

Development stage: Unknown
Lead developer: The Immune Response
Administration: Intramuscular, Subcutaneous

Overview

Amplivax is a proprietary biological adjuvant used as an immunological enhancer in therapeutic HIV vaccine studies. Specifically, it has been studied in combination with HIV-1 antigen vaccine formulations such as Remune to stimulate and augment HIV-specific immune responses in people with HIV/AIDS. Amplivax is formulated as HYB2055 and is administered in a protocol involving emulsification in incomplete Freund’s adjuvant. Its mechanism involves immune system stimulation, particularly the enhancement of CD4+ and CD8+ T cell responses to HIV antigens. The compound has been evaluated in Phase I/II and Phase III trials for its safety and efficacy as part of combination immunotherapeutic strategies[1][3][7].

Brand names: Amplivax
Other names: Amplivax HYB2055

Beyond the preview

Go deeper on Amplivax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amplivax.

Explore the full profile